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Germline Editing: Two Steps Forward, One Step Back?
Kristina M. Smith*
I. INTRODUCTION
As technology develops, the law which regulates technology must also
develop. Scientists and policymakers must decide what technology to create
and if our society will tolerate or approve these new creations. In particular,
the emerging technology in genetic editing is becoming a double-edged
sword. On one side, editing genes could revolutionize disease treatment and
help many families have children free of crippling hereditary diseases. But
on the other hand, gene editing could affirm certain traits as superior and lead
to a “designer-baby” industry where parents order children according to pref-
erence, like a customizable product. With diverging opinions and policies
supporting contradictory legal frameworks, Congress has many options. This
note discusses the various legal approaches of the states to genetic editing,
with a focus on germline editing. Based on this analysis, Congress is likely to
remove the prohibition on public funding for germline editing research but
retain its ban on clinical trials.
II. GERMLINE EDITING AND CRISPR
Genome editing involves the removal, replacement, or addition of ge-
netic material in any cell’s DNA sequence.1 Laboratory scientists edit DNA
sequences using specific “‘scissor’ proteins that can recognize a specific
piece of DNA amongst the entire genome and make a break in the double
helix” at the specific location.2 Scientists that edit genomes may use the
DNA break to alter the DNA sequence or to allow the DNA sequence to heal
incorrectly, which causes the gene it resides in to become inactive.3
There are two types of genome editing: somatic cell editing and
germline cell editing.4 Somatic cells make up most of the body’s cells and
contain nonhereditary genetic information.5 In contrast, germline cells make
up the body’s reproductive material including eggs, sperm, and embryo
cells.6
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Germline cells contain hereditary genetic information; therefore, the
cells “do transmit their DNA from generation to generation.”7 Both the cost
of errors and the results that may be achieved through germline editing are
great. The heritable nature of the genes affected makes germline editing criti-
cal to conduct accurately since any small error will be passed on genetically
to each new generation.8 Further, germline cell editing invites an ethical de-
bate over the safety of the process and the possibility of introducing commer-
cialized eugenics and designer babies.9
The latest technology in germline editing is a process called: Clustered
Regularly Interspaced Short Palindromic Repeats (CRISPR).10 Bacterium use
CRISPR to detect “invasive viral genetic material.”11 In 2012, scientists at
the University of California at Berkeley, led by Jennifer Doudna, discovered
how to use CRISPR for “targeting genes and potentially very short stretches
of a cell’s genome” and to slice a simple DNA strand with high precision.12
Then, in 2013, scientists at the Broad Institute of Harvard Medical School
and Massachusetts Institute of Technology worked together to discover a
specific application for CRISPR: editing animal and plant cell genomes.13
Both the Berkeley group and the Broad Institute group patented their discov-
eries, and there is an ongoing battle between the two groups of scientists over
whom owns the technology.14 The United States Patent Trial and Appeal
Board recently determined that the patents cover distinct inventions; there-
fore, both sets of patents are valid.15
7. Genome Editing and Stem Cells: Questions and Answers, supra note 1.
8. Id.
9. Tara R. Melillo, Note, Gene Editing and the Rise of Designer Babies, 50
VAND. J. TRANSNAT’L L. 757, 762 (2017). A complete discussion of the ethics
of germline editing is beyond the scope of this note.
10. Joel Achenbach & Carolyn Y. Johnson, Broad Institute Scientist Prevails in





13. Id.; Jon Cohen, Ding, Ding, Ding! CRISPR Patent Fight Enters Next Round,
SCIENCE (July 26, 2017, 9:00 AM), http://www.sciencemag.org/news/2017/07/
ding-ding-ding-crispr-patent-fight-enters-next-round.
14. Cohen, supra note 13.
15. Achenbach & Johnson, supra note 10. The scientists at Berkeley appealed the
decision to the United States Court of Appeals for the Federal Circuit. Cohen,
supra note 13. A more complete analysis of the patent battle is beyond the
scope of this note.
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The first human germline editing experiment in the world occurred in
China in 2015.16 This experiment was deemed unsuccessful because the em-
bryos experienced mosaicism.17 Scientists describe “mosaicism” as an em-
bryo where “changes were [not] taken up [ ] by all of the cells.”18 After the
negative results of the Chinese experiment, many organizations called for a
halt on germline editing research until it could be better understood.19 The
experiment vaulted germline editing onto the world stage in a negative light,
one that researchers in the field have been working to shed ever since.20
In July 2017, the first human germline editing experiment in the United
States occurred at the Oregon Health and Science University.21 Although still
far from clinical trials, the experiment was deemed a success because it sig-
nificantly minimized the flaws of the Chinese experiment.22 Shoukhrat
Mitalipov from the Oregon Health and Science University led the effort to
edit the germline of multiple single-cell embryos using CRISPR.23 The re-
searchers created the embryos by “fertiliz[ing] eggs with the sperm of a man
who has [a] mutation that causes the heart condition.”24 Researchers did not
intend for the experiment to result in reproduction, so the embryos only ex-
isted a few days.25 Some experts in the United States, like Jennifer Doudna,26
view the American experiment as encouragement for further research and for
possible, future clinical trials.27 The American experiment was a huge step
16. Ariana Eunjung Cha, First Human Embryo Editing Experiment in U.S. ‘Cor-








19. Britt E. Erickson, Editing of Human Embryo Genes Raises Ethics Questions,
CHEM. & ENG’G NEWS, June 29, 2015, at 20–21, https://cen.acs.org/articles/93/
i26/Editing-Human-Embryo-Genes-Raises.html.
20. Id.
21. Connor, supra note 17.
22. The American experiment showed significantly less mosaicism in the cells. Id.
23. Id.
24. Alessandra Potenza, Human Embryos Edited for First Time in U.S. Using
CRISPR, VERGE (Aug. 2, 2017, 1:59 PM), https://www.theverge.com/2017/7/
27/16049340/human-embryos-dna-crispr-gene-editing-us.
25. Connor, supra note 17.
26. Dounda discovered CRISPR use for slicing DNA at the University of Califor-
nia at Berkeley. Achenbach & Johnson, supra note 10.
27. Potenza, supra note 24.
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toward remedying the bad image projected from the 2015 Chinese experi-
ment. Germline editing is primed for its resurgence on the world stage, so
now is the time that legislation must change this resurgence.
III. LEGAL BACKGROUND IN THE UNITED STATES
The Dickey-Wicker Amendment, passed in 1996, prohibits the Depart-
ment of Health and Human Services from funding research on human em-
bryos.28 The relevant provision of the statute bans researchers from using
public funds to create an embryo solely for research purposes or for any
research that subjects an embryo to risk of injury or death.29 Congress at-
taches the Dickey-Wicker Amendment to the Departments of Health and
Human Services, Labor, and Education Appropriations Bill every year.30
In 2001, the Senate introduced an amendment to the Bipartisan Patient
Protection Bill.31 The amendment attempted to ban germline modification
outright,32 but the amendment was withdrawn the next day, despite having a
simple majority vote in its favor.33 In the legislative record, Senator Brown-
back, who proposed the amendment, withdrew it to “tighten up the language”
of the amendment for more votes and planned to reintroduce the amendment
again before germline editing research began in the United States.34
Shortly after the first experiment in China in 2015, the National Institute
of Health (NIH) voluntarily abstained from clinical trials for germline edit-
ing; it will continue the moratorium until more is known about the risks.35
Also concerned about risks, Congress added an amendment to the Consoli-
dated Appropriations Act for 2016, prohibiting the Food and Drug Adminis-
tration (FDA) from accepting applications for “research in which a human
embryo is intentionally created or modified to include a heritable genetic
modification.”36 Many scholars, like Glenn Cohen37 and Eli Adashi,38 believe
Congress included the FDA amendment in the Appropriations Act because
28. Balanced Budget Downpayment Act, I, Pub. L. No. 104-99, 110 Stat. 26
(1996).
29. Id.
30. Eileen M. Kane, Human Genome Editing: An Evolving Regulatory Climate, 57
JURIMETRICS J. 301, 313 (2017).
31. 147 CONG. REC. S7011, 7066–68 (daily ed. June 28, 2001) (statement of Sen.
Brownback), available at https://www.congress.gov/crec/2001/06/28/CREC-
2001-06-28-pt1-PgS7011-7.pdf.
32. Id.
33. 147 CONG. REC. S7131 (daily ed. June 29, 2001) (statement of Sen.
Brownback).
34. Id.
35. Erickson, supra note 19.
36. Consolidated Appropriations Act, Pub. L. No. 114–113, 129 Stat. 2242, 2283
(2015).
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there has not been enough support in recent years to pass a specific germline
editing bill.39 Further, the FDA amendment received additional protection as
a part of an appropriations bill, which was important to government function;
therefore, Congress and the president were less likely to object to a small
piece of the omnibus bill.40 Congress again attached the FDA amendment to
the Consolidated Appropriations Act for 2017.41
The 2017 appropriations bill also included an amendment that required
the Office of the Director of National Intelligence to formulate a plan to
“monitor advances in life sciences and biotechnology that addresses . . .
[United States] competitiveness in the global bio-economy and the risks and
threats in genetic editing technologies,” such as CRISPR.42 In July 2017, the
House of Representatives Committee on Appropriations submitted its annual
report, which covers FDA funding.43 The report acknowledged that germline
editing could benefit the country but determined that “researchers do not yet
fully understand all the possible side effects of editing the genes of a human
embryo.”44 But, Congress must make the decision every year whether to al-
low federal funding for germline research, since appropriations bills occur
annually.45 Therefore, technological advancements and changes in policy
may influence Congress toward the deregulation of germline research.
In February 2017, the National Academy of Sciences released a consen-
sus report from its international summit with China and the United Kingdom
in December 2015.46 The summit discussed germline editing and formulated
an international policy stance.47 Despite disagreement over where to draw the
line, all parties agreed that ethical issues should weigh heavily and the inter-
37. Cohen is a Professor of Law at Harvard Law School and Director of the Petrie-
Flom Center for Health Law Policy, Biotechnology, and Bioethics. See I.
Glenn Cohen & Eli Y. Adashi, FDA is Prohibited from Going Germline, SCI.,
Aug. 5, 2016, at 545.
38. Adashi is a Professor of Medical Science at Brown University. Id.
39. Id.
40. Id.
41. Consolidated Appropriations Act, Pub. L. No. 115-31, 131 Stat. 135, 173
(2017).
42. Id. § 606.
43. H.R. REP. NO. 115-232, at 68 (2017).
44. Id.
45. Glossary Term — Appropriation, UNITED STATES S., https://www.senate.gov/
reference/glossary_term/appropriation.htm (last visited Mar. 20, 2018).
46. Andrew P. Han, NAS Human Genome Editing Report Braces for Germline
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national policy should favor caution.48 The summit’s organizing committee,
which produced the policy stance of the summit, included biologists and
bioethicists from a variety of countries.49 The policy recommendations en-
courage preclinical research essential for curing disease but limited the use of
clinical trials.50
A. American Society of Human Genetics Statement
In reaction to the recent experiment in the United States, the American
Society of Human Genetics (ASHG) issued a statement about germline edit-
ing research policy on August 3, 2017.51 ASHG advocated for restrictions
that would not hinder the progress of safe experimentation.52 The statement
recommended against “germline gene editing that culminate[d] in human
pregnancy” due to the “nature and number of unanswered scientific, ethical,
and policy questions.”53 ASHG also promoted publicly funding “research on
the possible future clinical applications of gene editing.”54 The group advo-
cated that such research could be done safely, using “in vitro germline gen-
ome editing on human embryos and gametes, with appropriate oversight and
consent from donors.”55 But, before clinical research can proceed, there must
be: “(a) a compelling medical rationale, (b) an evidence base that supports its
clinical use, (c) an ethical justification, and (d) a transparent public process to
solicit and incorporate stakeholder input.”56 Many groups from around the
world endorsed the ASHG statement.57
48. Id.
49. See On Human Gene Editing: International Summit Statement, NAT’L ACAD.
OF SCI., ENG’G, & MED. (Dec. 3, 2015), http://www8.nationalacademies.org/on
pinews/newsitem.aspx?RecordID=12032015a.
50. See id.
51. See generally Ormond et al., Human Germline Genome Editing, 101 AM. J.
HUM. GENETICS 167 (2017), http://www.sciencedirect.com/science/article/pii/
S0002929717302471?via%3Dihub (indicating that representatives from the
United Kingdom Association of Genetic Nurses and Counsellors, Canadian As-
sociation of Genetic Counsellors, International Genetic Epidemiology Society,
and United States National Society of Genetic Counselors worked together
with ASHG to formulate the statement).
52. Id. at 169.
53. Id. at 172.
54. Id. at 167.
55. Id. at 173.
56. Ormond et al., supra note 51.
57. Among them are “the American Society for Reproductive Medicine, Asia Pa-
cific Society of Human Genetics, British Society for Genetic Medicine, Human
Genetics Society of Australasia, Professional Society of Genetic Counselors in
Asia, and Southern African Society for Human Genetics.” Id.
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The policy advocated by ASHG conflicts with Congress’ current law
prohibiting the use of federal funds for germline editing. As international and
domestic groups increasingly support relaxed regulations, Congress will
likely feel pressure to reconsider its stance on funding research. When con-
sidering how best to proceed, Congress is likely to look for inspiration
among the states.58
B. Development in the States: Different Perspectives
Many people, even within the United States, disagree over the best legal
approach to germline editing. Some people, like Marcy Darnovsky, find
moral problems with the practice and want a complete ban on germline edit-
ing research.59 Many others, like R. Alta Charo, call for regulation, but not an
outright prohibition on germline editing.60 These different perspectives show
up in state laws.61 Congress may consider the states as laboratories for de-
mocracy in this area. While germline editing is such a new field that few
states have yet to specifically and directly address it, state laws regarding
embryonic research provide insight to the activities scientists engage in for
germline editing.
South Dakota is one of the few states with a current ban on any embry-
onic research that does not protect the life or health of the embryo.62 Under
its state law, a human embryo includes single-cells living outside of the
womb.63 South Dakota prohibits any “nontherapeutic research that destroys a
human embryo.”64 In another section, the law bans research that “subjects a
58. A discussion of other countries’ policies and regulations is beyond the scope of
this note.
59. Marcy Darnovsky, Con: Do Not Open the Door to Editing Genes in Future
Humans, NAT’L GEOGRAPHIC, http://www.nationalgeographic.com/magazine/
2016/08/human-gene-editing-pro-con-opinions/ (last visited Sept. 4, 2018).
60. Pat Schneider, UW’s Alta Charo: Gene Editing for Inherited Human Traits




61. See 410 ILL. COMP. STAT. ANN. 110/1–/50 (West 2008); MONT. CODE ANN.
§ 50-11-103 (West 2009); NEB. REV. STAT. ANN. §§ 28-346, 71-7606(3) (West
1979); S.D. CODIFIED LAWS §§ 34-14-16–17, 20 (2000).
62. Embryonic and Fetal Research Laws, NAT’L CONF. STATE LEGIS. (Jan. 1,
2016), http://www.ncsl.org/research/health/embryonic-and-fetal-research-laws
.aspx (showing that germline editing at this early stage of research falls under
this ban because the embryos die at the completion of research since the re-
search is not yet ready for reproductive trials).
63. S.D. CODIFIED LAWS § 34-14-20 (2000).
64. Id. § 34-14-16.
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human embryo to substantial risk of injury or death.”65 Congress is not likely
to use South Dakota as a model for legislation since Congress has never
banned germline editing, despite recognizing the risks.66
Nebraska takes a policy position similar to the federal government.67
Nebraska permits embryonic research so long as the research subject is not
an aborted live fetus.68 Yet, the state prohibits the use of state funds from the
Nebraska Health Care Funding Act for embryonic research.69 Without any
policy change, Congress will continue employing this type of regulatory
scheme. But change is likely to occur after the recent experiment in the
United States and policy recommendations by multiple scientific organiza-
tions. It appears increasingly likely that Congress will amend its regulatory
scheme with each new advancement of science, making the possibility of
health-based germline editing less risky.
Illinois is among the many states that not only allows embryonic re-
search, but also provides public funding for the research.70 In 2008, Illinois
enacted a statute that permits funding for, and promotes research on, human
embryonic germ cells.71 The state law favors embryonic research, providing
that “[r]esearch involving the derivation and use of . . . human embryonic
germ cells . . . shall be permitted and the ethical and medical implications of
this research shall be given full consideration.”72 Further, the permitted re-
search “shall be allowed to receive public funds through a program estab-
lished specifically for the purpose of supporting stem cell research in Illinois
under the Department of Public Health.”73
Illinois recognized that the federal government was not providing fund-
ing in this area of great importance and innovation, so it developed a law that
brings the advantages of embryonic research to Illinois. The purposes for
creating the program are manifold.74 First, the Illinois legislature wants “to
improve the health of the citizens of Illinois through stem cell research.”75
The legislature also wants “to support scientific research in Illinois for which
funding from the U.S. government is currently restricted, namely human em-
65. Id. § 34-14-17.
66. Id. §§ 34-14-16–17, 20.
67. Embryonic and Fetal Research Laws, supra note 62.
68. NEB. REV. STAT. ANN. § 28-346 (West 1979).
69. Id. § 71-7606(3).
70. Embryonic and Fetal Research Laws, supra note 62.
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bryonic stem cell research.”76 Further, the statute means “to improve the na-
tional competitive position of Illinois in the field of regenerative medicine.”77
Finally, Illinois seeks “to promote the translation of stem cell research into
clinical practice and the transfer of technology to biomedical and technologi-
cal industry.”78
The law of Illinois values progress and the health of its citizens over the
risk of unknown certainty of using CRISPR.79 This approach mirrors the rec-
ommendations of the recent ASHG statement.80 The federal government also
has an interest in remaining competitive “in the global bio-economy,” as
shown from Congress’s change between the 2016 and 2017 appropriations
bills.81 Therefore, Congress will likely soon take this inclusive path since the
new approach balances those concerned with the ethics of designer babies
and those who desire germline editing to cure crippling diseases. This path
provides a happy medium that allows for research in a controlled, health-
focused manner.
Montana falls within the diminishing minority of states that remains
largely unregulated.82 The only mention to embryos addresses cloning.83 A
pertinent piece of the law, however, distinctly leaves the field open beyond
cloning, stating that “[n]othing in this section prohibits embryonic stem cell
research using embryonic stem cell lines of uncloned origin.”84 Although it
seems likely that Congress will decide to remove its prohibition of using
public funds, bioethicists’ concerns prevent a complete deregulation from oc-
curring in the near future. Further, people become accustomed to regulations,
making it difficult to put the proverbial genie back in the bottle.85 Both state-
ments by prominent scientific organizations recommend against unrestrained
germline editing and recognize that research is not yet ready to progress to
76. Id.
77. 410 ILL. COMP. STAT. ANN. 110/1–/50(b).
78. Id.
79. See id. 110/1–/50.
80. See Ormond et al., supra note 51.
81. Compare Consolidated Appropriations Act, 2017, 115 Pub. L. 31, Div. N,
§ 606, (May 5, 2017) https://www.congress.gov/bill/115th-congress/house-bill/
244 (including a directive to monitor how competitive the United States is in
the global genetic editing field), with Consolidated Appropriations Act, 2016,
114 Pub. L. 113 (Dec. 18, 2015) (containing no similar directive to monitor).
82. See Embryonic and Fetal Research Laws, supra note 62.
83. MONT. CODE ANN. § 50-11-103 (West 2009).
84. Id. § 50-11-103(3).
85. See Sergio Hernandez, Cutting Regulations is Not So Easy, CNN (Jan. 31,
2017, 7:01 PM ET), http://www.cnn.com/2017/01/31/politics/trump-regula-
tions-executive-order/index.html.
110 SMU Science and Technology Law Review [Vol. XXI
clinical trials.86 Furthermore, the possibility that scientists will commercialize
germline editing to produce designer babies and propagate eugenics seems to
make deregulation impossible now that scientists in the United States are
conducting germline editing experiments. Bioethicists and lawmakers are un-
likely to allow scientists with the appropriate technology and monetary in-
centive to proceed without supervision.
Based on the large majority of states that allow public funding for em-
bryonic research, Congress is likely to allow public funding for embryonic
research. Outside influences this year from both the NAS International Sum-
mit and the ASHG internationally sponsored statement are encouraging Con-
gress to keep its restrictions on reproductive clinical trials but allow funding
on early-stage research.87 Finally, the successful experiment in the United
States this year shows that germline editing can become safer with increased
research, which will lead to increased funding.88
For those concerned about scientific overreach, Arthur Caplan, a
bioethicist at New York University believes the scientific community can
help solve the problem.89 He proposes that eugenics can simply be avoided
by line drawing.90 He asserts that line drawing will be effective if
“[s]cientists and bioethicists [ ] agree on rules on what should and should not
be done, and then make sure that editors of scientific journals enforce
them.”91 If scientists cannot get their research published, there will likely be
less incentive to conduct impermissible research.92 In terms of Congressional
restrictions, Caplan thinks funding should be available through a review
committee that can permit funding for health-based research and refuse fund-
ing for designer baby experiments.93 Ideally, safe and health-oriented re-
search can be achieved if journals, private foundations, patient groups, and
government work together.94
IV. CONCLUSION
No matter what decision Congress makes in the near future, law in the
area of germline editing will affect important aspects of American life.
CRISPR can save lives and help families that suffer from reproductive and
health problems, but it can also facilitate eugenics and create controversy
86. See Han, supra note 46; Ormond et al., supra note 51.
87. See Han, supra note 46; Ormond et al., supra note 51.
88. Connor, supra note 17.
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over disabilities and class differences. Congress has many routes to influence
its future treatment of germline editing, primarily the treatment of embryonic
research by individual states. After weighing the value of the technology
against the public policy concerns, Congress will likely start allowing public
funds to be spent on safe, nonreproductive research in germline editing. But
it will also reserve an assessment of clinical trials until after researchers
know more about the risks and solutions. This choice of funding will en-
courage scientists to keep experimenting in the United States and promote
healthy technological developments that will save lives.
